These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 34146243)
1. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243 [TBL] [Abstract][Full Text] [Related]
2. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
3. The Correlation Between [ Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
7. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors. Menon BK; Kalshetty A; Bhattacharjee A; Basu S Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598 [TBL] [Abstract][Full Text] [Related]
8. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [TBL] [Abstract][Full Text] [Related]
9. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
11. The comparison of three different molecular imaging methods in localization and grading of insulinoma. Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Somatostatin Receptor-Derived Volumetric Parameters from a Hybrid Standardized Uptake Value Thresholding Method in Patients with 68Ga-DOTATATE-Avid Stage IV Neuroendocrine Neoplasms: A Preliminary Study. Cheng Z; Zou S; Zhou J; Song S; Zhu Y; Zhao J; Zhu X Neuroendocrinology; 2024; 114(9):805-815. PubMed ID: 37088082 [TBL] [Abstract][Full Text] [Related]
13. Parametric net influx rate imaging of Yin H; Liu G; Mao W; Lv J; Yu H; Cheng D; Cai L; Shi H Ann Nucl Med; 2024 Jul; 38(7):483-492. PubMed ID: 38573411 [TBL] [Abstract][Full Text] [Related]
14. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243 [TBL] [Abstract][Full Text] [Related]
15. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584 [TBL] [Abstract][Full Text] [Related]
16. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927 [TBL] [Abstract][Full Text] [Related]
17. Clinical and Prognostic Value of PET/CT Imaging with Combination of Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780 [TBL] [Abstract][Full Text] [Related]
18. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600 [TBL] [Abstract][Full Text] [Related]
19. Semiautomatic Tumor Delineation for Evaluation of Carlsen EA; Johnbeck CB; Loft M; Pfeifer A; Oturai P; Langer SW; Knigge U; Ladefoged CN; Kjaer A J Nucl Med; 2021 Nov; 62(11):1564-1570. PubMed ID: 33637589 [TBL] [Abstract][Full Text] [Related]
20. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors. Komek H; Can C; Urakçi Z; Kepenek F Nucl Med Commun; 2019 May; 40(5):517-524. PubMed ID: 30694875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]